Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamideShannon R. McCurdy, Yvette L. Kasamon, Amy E. DeZern et al.|Blood|2015Cited by 299
Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamideShannon R. McCurdy, Leo Luznik, Yvette L. Kasamon et al.|Haematologica|2016Cited by 187
Absence of Post-Transplantation Lymphoproliferative Disorder after Allogeneic Blood or Marrow Transplantation Using Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease ProphylaxisJennifer A. Kanakry, Richard F. Ambinder, Yvette L. Kasamon et al.|Biology of Blood and Marrow Transplantation|2013Cited by 114
Outcomes of Related Donor HLA-Identical or HLA-Haploidentical Allogeneic Blood or Marrow Transplantation for Peripheral T Cell LymphomaJennifer A. Kanakry, Richard F. Ambinder, Yvette L. Kasamon et al.|Biology of Blood and Marrow Transplantation|2013Cited by 88
Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation with High Dose, Post-Transplantation CyclophosphamideAshley Munchel, Ephraim J. Fuchs, Chimen Kesserwan et al.|Pediatric Reports|2011Cited by 84